Your browser doesn't support javascript.
loading
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.
Ko, J J; Choueiri, T K; Rini, B I; Lee, J-L; Kroeger, N; Srinivas, S; Harshman, L C; Knox, J J; Bjarnason, G A; MacKenzie, M J; Wood, L; Vaishampayan, U N; Agarwal, N; Pal, S K; Tan, M-H; Rha, S Y; Yuasa, T; Donskov, F; Bamias, A; Heng, D Y C.
Afiliación
  • Ko JJ; Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada.
  • Choueiri TK; Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Rini BI; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
  • Lee JL; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Kroeger N; 1] Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada [2] Department of Urology, Universitätsmedizin Greifswald, Greifswald, Germany.
  • Srinivas S; Division of Oncology, Stanford Medical Center, Stanford, California, USA.
  • Harshman LC; Division of Oncology, Stanford Cancer Institute, Stanford School of Medicine, Stanford, California, USA.
  • Knox JJ; Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Bjarnason GA; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
  • MacKenzie MJ; London Health Sciences Center, London, Ontario, Canada.
  • Wood L; Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
  • Vaishampayan UN; Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.
  • Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Pal SK; City of Hope Comprehensive Cancer Center, Medical Oncology & Experimental Therapeutics, Duarte, California, USA.
  • Tan MH; National Cancer Center, Institute of Bioengineering and Nanotechnology, Singapore, Singapore.
  • Rha SY; Yonsei University Hospital, Seoul, South Korea.
  • Yuasa T; Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Donskov F; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Bamias A; Alexandra Peripheral General Hospital, Athens, Greece.
  • Heng DY; Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada.
Br J Cancer ; 110(8): 1917-22, 2014 Apr 15.
Article en En | MEDLINE | ID: mdl-24691425
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Factor A de Crecimiento Endotelial Vascular / Serina-Treonina Quinasas TOR / Terapia Molecular Dirigida Tipo de estudio: Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Factor A de Crecimiento Endotelial Vascular / Serina-Treonina Quinasas TOR / Terapia Molecular Dirigida Tipo de estudio: Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Canadá